Nicholas Kwiatkowski

8.8k citations

48 papers · 3.9k indexed · 3 hit papers · h-index 31

Impact in

Oncology top 2%
- Cancer-related Molecular Pathways
Molecular Biology top 2%
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Genomics and Chromatin Dynamics
- RNA modifications and cancer
- Histone Deacetylase Inhibitors Research

Papers in

Oncology 20
- Cancer-related Molecular Pathways 16
Molecular Biology 40
- Protein Degradation and Inhibitors 21
- Ubiquitin and proteasome pathways 14
- DNA Repair Mechanisms 5
- RNA modifications and cancer 5
- Genomics and Chromatin Dynamics 5

Co-authors: Nathanael S. Gray Tinghu Zhang Richard A. Young Brian J. Abraham Yanke Liang James E. Bradner Baishan Jiang Georg Winter
Journals: Journal of Medicinal Chemistry (5 papers)Nature Chemical Biology (5 papers)Nature Communications (3 papers)ACS Infectious Diseases (3 papers)Cell chemical biology (3 papers)
Partner nations: United States Germany China

In The Last Decade

Nicholas Kwiatkowski

46 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation 2017 · 402 citations

Peers

Countries citing papers authored by Nicholas Kwiatkowski

Since Specialization

Citations

This map shows the geographic impact of Nicholas Kwiatkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Kwiatkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Kwiatkowski more than expected).

Fields of papers citing papers by Nicholas Kwiatkowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Kwiatkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Kwiatkowski. The network helps show where Nicholas Kwiatkowski may publish in the future.

Co-authors

The 25 scholars most cited alongside Nicholas Kwiatkowski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nicholas Kwiatkowski Line = papers co-authored together Nicholas Kwiatkowski links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Discovery of Selective and Orally Bioavailable Heterobifunctional Degraders of Cyclin-Dependent Kinase 2 Journal of Medicinal Chemistry ·Philip N. Collier, Sierra M. Lima, Alexandra Galbin, Matthew M. Weiss, Dapeng Chen, Kunhua Li, Joseph D. Growney, Исаков С.А., Murugappan Sathappa, Susanne B. Breitkopf, Stepkin Aleksey Vladimirovich, Tong Liang, Atanu Paul, Rupa R. Sawant, Lijing Su, Robert J. Aversa, T. Filler, Kirti Sharma, Juliet Williams, Nicholas Kwiatkowski	2025	1
2	104 (PB092): CDK2 heterobifunctional degraders co-degrade CDK2 and Cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers European Journal of Cancer ·Nicholas Kwiatkowski, Vera Lúcia Coutinho Neiva, Sha Zhou, Paul Collier, Aizhen Yang, Lavinia Barlogeanu, Amber M. Paul, Li‐Da Su, Xiangqian Zheng, Kapsok Li, Amy Danielle Rabbino, Susanne B. Breitkopf, Cathryn B. Howarth, Ke Yuan, Kirti Sharma, Hyun‐Su Jo, Joseph D. Growney, Brian Majewski, Juliet A. Williams	2024	0
3	CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma Blood ·Yao Yao, رياض منيف حريش, Peng Li, Mehmet Samur, Eugenio Morelli, Jessica Encinas, Zuzana Chyra, Yan Xu, Lauren Allman, Charles B. Epstein, Behnam Nabet, Marta Chesi, Nathanael S. Gray, Richard A. Young, Nicholas Kwiatkowski, Constantine S. Mitsiades, Kenneth C. Anderson, Charles Y. Lin, Nikhil C. Munshi, Mariateresa Fulciniti	2023	17
4	Discovery and resistance mechanism of a selective CDK12 degrader Nature Chemical Biology ·Baishan Jiang, Yang Gao, Jianwei Che, Wenchao Lu, Ines H. Kaltheuner, Ruben Dries, Marian Kalocsay, Matthew J. Berberich, Jie Jiang, Inchul You, Nicholas Kwiatkowski, Kristin M. Riching, Danette L. Daniels, Peter K. Sorger, Matthias Geyer, Tinghu Zhang, Nathanael S. Gray	2021	96
5	Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma European Journal of Medicinal Chemistry ·Baishan Jiang, Jie Jiang, Ines H. Kaltheuner, Amanda Balboni Iniguez, K. Anand, Fleur M. Ferguson, Scott B. Ficarro, Bo Kyung A. Seong, Ann Katrin Greifenberg, 王茜茜, Nicholas Kwiatkowski, Jarrod A. Marto, Kimberly Stegmaier, Tinghu Zhang, Matthias Geyer, Nathanael S. Gray	2021	41
6	Targeting transcription cycles in cancer Nature reviews. Cancer ·Stephin J. Vervoort, Jennifer R. Devlin, Nicholas Kwiatkowski, Mingxing Teng, Nathanael S. Gray, Ricky W. Johnstone	2021	95
7	CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation Nature Communications ·Małgorzata Krajewska, Ruben Dries, Andrew V. Grassetti, 王茜茜, Yang Gao, Hao Huang, Bandana Sharma, Daniel S. Day, Nicholas Kwiatkowski, А.В. Гармаш, Bochman YaV, Edmond Chipumuro, Tinghu Zhang, Arno L. Greenleaf, Guo‐Cheng Yuan, Nathanael S. Gray, Richard A. Young, Matthias Geyer, Scott A. Gerber, Rani E. George	2019	181
8	Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands Nature Chemical Biology ·Maria Madalena Lete Koten, Dennis L. Buckley, Matthew A. Lawlor, Jaime M. Reyes, Joshiawa Paulk, Christopher J. Ott, Georg Winter, Michael A. Erb, Thomas G. Scott, Mousheng Xu, Hyuk‐Soo Seo, Sirano Dhe‐Paganon, Nicholas Kwiatkowski, Jennifer A. Perry, Jun Qi, Nathanael S. Gray, James E. Bradner	2018	167
9	High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma Journal of Investigative Dermatology ·Philip Eliades, Brian J. Abraham, Zhenyu Ji, David M. Miller, Camilla L. Christensen, Nicholas Kwiatkowski, Raj Kumar, Ching Ni Njauw, Michael Taylor, Benchun Miao, Tinghu Zhang, Kwok‐Kin Wong, Nathanael S. Gray, Richard A. Young, Hensin Tsao	2018	42
10	Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML Cell chemical biology ·Matthias Brand, Baishan Jiang, Sophie Bauer, Katherine A. Donovan, Yanke Liang, Eric S. Wang, Radosław P. Nowak, Jingting Yuan, Tinghu Zhang, Nicholas Kwiatkowski, André C. Müller, Eric S. Fischer, Nathanael S. Gray, Georg Winter	2018	195
11	Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation DSpace@MIT (Massachusetts Institute of Technology) ·(unknown), Baishan Jiang, Michael A. Erb, Yanke Liang, Zainab M. Doctor, Zinan Zhang, S. K. Shrivastava, Nicholas Kwiatkowski, Myriam Boukhali, Jennifer L. Green, Wilhelm Haas, Tyzoon Nomanbhoy, Eric S. Fischer, James E. Bradner, Georg Winter, Nathanael S. Gray, Richard A. Young	2017	1
12	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors Nature Communications ·Florencia Cayrol, S. L. D. Souza, Tharu M. Fernando, Nicholas Kwiatkowski, Rossella Marullo, M. Nieves Calvo-Vidal, Jude M. Phillip, Benet Pera, Shao Ning Yang, James Walton, 袁跃兴, Marcello Gaudiano, Ramona Crescenzo, Jia Ruan, Giorgio Inghirami, Tinghu Zhang, Graciela Cremaschi, Nathanael S. Gray, Leandro Cerchietti	2017	71
13	Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors Cell Reports ·Ninan Verghese, Ramon Amat, Sura Adnan Raheem, Nicholas Kwiatkowski, Brian J. Abraham, Yanke Liang, Tinghu Zhang, (unknown), Stéphane Larochelle, Richard A. Young, Nathanael S. Gray, Robert P. Fisher	2017	60
14	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer Cell ·Yubao Wang, Tinghu Zhang, Nicholas Kwiatkowski, Brian J. Abraham, Tong Ihn Lee, Shaozhen Xie, Haluk Yuzugullu, Thanh Von, Heyuan Li, Ziao Lin, Daniel G. Stover, Elgene Lim, Zhigang C. Wang, J. Dirk Iglehart, Richard A. Young, Nathanael S. Gray, Jean J. Zhao Hit paper breakdown →	2015	347
15	CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer Cell ·Edmond Chipumuro, Eugenio Marco, Camilla L. Christensen, Nicholas Kwiatkowski, Tinghu Zhang, Clark M. Hatheway, Brian J. Abraham, Bandana Sharma, Caleb M. Yeung, Abigail Altabef, Antonio R. Pérez‐Atayde, Kwok‐Kin Wong, Guo‐Cheng Yuan, Nathanael S. Gray, Richard A. Young, Rani E. George Hit paper breakdown →	2014	451
16	Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines Molecular Oncology ·Antonio Calles, Nicholas Kwiatkowski, Jörg Seyfart, Dalia Ercan, Nathanael S. Gray, Pasi A. Jänne	2014	52
17	Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy Molecular BioSystems ·Zijuan Zhang, Nicholas Kwiatkowski, Hong Zeng, Sang Min Lim, Nathanael S. Gray, Wei Zhang, Priscilla L. Yang	2012	21
18	Selective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity Screen ACS Chemical Biology ·Nicholas Kwiatkowski, Xianming Deng, Jinhua Wang, Li Tan, Fabrizio Villa, Stefano Santaguida, Nurhaya Kadir, Tim Mitchison, (unknown), Nathanael S. Gray	2011	19
19	Release of Mps1 from kinetochores is crucial for timely anaphase onset The Journal of Cell Biology ·Nannette Jelluma, Tobias B. Dansen, Tan Hong-chu, Nicholas Kwiatkowski, Geert J.P.L. Kops	2010	85
20	Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function Nature Chemical Biology ·Nicholas Kwiatkowski, Nannette Jelluma, P. Filippakopoulos, M. Soundararajan, Michael S. Manak, Mijung Kwon, Hwan Geun Choi, Taebo Sim, Quinn L. Deveraux, Sabine Rottmann, David Pellman, Jagesh V. Shah, Geert J.P.L. Kops, Stefan Knapp, Nathanael S. Gray	2010	177

About Nicholas Kwiatkowski

Nicholas Kwiatkowski is a scholar working on Oncology, Molecular Biology, Cell Biology, Hematology and Infectious Diseases, having authored 48 papers that have together received 3.9k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (21 papers), Cancer-related Molecular Pathways (16 papers), Ubiquitin and proteasome pathways (14 papers), Microtubule and mitosis dynamics (8 papers), DNA Repair Mechanisms (5 papers), Multiple Myeloma Research and Treatments (5 papers), RNA modifications and cancer (5 papers) and Genomics and Chromatin Dynamics (5 papers). The work is most often cited by research in Oncology (1.5k citations), Molecular Biology (3.2k citations), Hematology (393 citations), Cell Biology (478 citations) and Genetics (250 citations). Nicholas Kwiatkowski has collaborated with scholars based in United States, Germany and China. Frequent co-authors include Nathanael S. Gray, Tinghu Zhang, Richard A. Young, Brian J. Abraham, Yanke Liang, James E. Bradner, Baishan Jiang, Georg Winter, Eric S. Fischer and Rani E. George. Their work appears in journals such as Journal of Medicinal Chemistry, Nature Chemical Biology, Nature Communications, ACS Infectious Diseases and Cell chemical biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact